Morgan Stanley assumed coverage of Integra LifeSciences (IART) with an Underweight rating with a price target of $20, down from $25. The firm maintains concerns regarding the company’s execution against its topline growth and margin expansion initiatives, calling it a “show-me” story.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences price target raised to $26 from $21 at Truist
- Integra LifeSciences price target raised to $22 from $16 at Citi
- Integra LifeSciences Announces Q3 2024 Financial Results
- Nvidia to replace Intel on DJIA, Berkshire reports Q3 results: Morning Buzz
- Morning Movers: Air Transport Services jumps following $3.1B take-private deal